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Background: The systemic treatment of malignant endometrial stromal tumors (EST) is not well established. A few
reports describe objective responses to imatinib, which suggest a novel therapeutic strategy for these tumors. Due
to these facts, we aimed to perform a retrospective analysis of possible molecular targets of tyrosine kinase
inhibitors (TKI) in EST: KIT, PDGFRA and EGFR.
Methods: 52 endometrial stromal sarcomas and 13 undifferentiated endometrial sarcomas were examined and
reviewed. Mutational analysis were performed for exons 9, 11, 13, and 17 of the KIT gene, exons 12 and 18 of the
PDGFRA gene and exons 18, 19, 20 and 21 of the EGFR gene. The incidence and distribution of the KIT, PDGFRA,
and EGFR expression were examined by immunohistochemistry, and EGFR amplification was assessed by
fluorescence in situ hybridization.
Results: No mutations in KIT, PDGFRA and EGFR genes were detected. Overexpression of KIT, PDGFRA, EGFR, was
detected in 2 (3%), 23 (35.4%), 7 (10.8%) cases respectively, whereas amplification of EGFR gene was not found.
Conclusions: Absence of significant expression, amplification and activating mutations on these tyrosine kinase
receptors suggest that it is unlikely that EST can benefit from therapies such as TKI on the systemic setting.
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Endometrial stromal sarcoma, low grade (ESS) and undif-
ferentiated endometrial sarcoma (UES) belong to the rare
group of endometrial stromal tumors (EST), which repre-
sents 15% of uterine sarcomas [1]. ESS presents a cellular
background similar to the cells of normal endometrial
stroma in proliferative phase. In contrast, UES lacks spe-
cific differentiation and bears no histological resemblance
to endometrial stroma. Tumor cells are high-grade spindle
to polygonal-shaped, with marked nuclear pleomorphism
and high mitotic activity. Necrosis and vascular invasion
are commonly seen [2]. While ESS is characterized by* Correspondence: edealava@usal.es
†Equal contributors
2Centro de Investigación del Cáncer-IBMCC USAL-CSIC, Salamanca, Spain
Full list of author information is available at the end of the article
© 2013 Sardinha et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orindolent course and late recurrences, with a 5-year overall
survival (OS) up 70%, UES is usually diagnosed at
advanced stages, and has a high rate of distant metastasis
and a 5-year OS ranging from 25-55% [3-6]. FIGO stage
[7] is the strongest prognostic factor for these malignan-
cies [5,8]. CD10 is the most sensitive marker for ESS
[9,10]. Estrogen and progesterone receptors [11] and
aromatase [12] are usually expressed in ESS, and less
commonly in UES [13-15]. The rearrangement t(7;17)
(p15;q21), which results in JAZF1/JJAZ1 gene fusion, is
the cytogenetic hallmark of ESS [16], although other
translocations have been reported [17-19]. In contrast,
UES is characterized by a complex karyotype [20,21].
Recently, the t(10;17)(q22;p13) that results in YWHAE-
FAM22A/B gene fusion with oncogenic properties was
reported in a subset of UES [22], which is associated to
the expression of Cyclin D1 [23,24] and β-catenin [23];al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Surgery is the standard treatment, and includes total hys-
terectomy and bilateral salpingo-oophorectomy. However,
due the rarity of these tumors, distinct clinical behavior,
and lack of randomized studies including both categories,
an appropriate systemic treatment of these malignancies
was not been yet established.
Molecular targets of tyrosine kinase inhibitors (TKI)
such as imatinib mesylate (GlivecW, STI-571, Novartis,
Switzerland), gefitinib (IressaW, AstraZeneca, Macclesfield,
UK) and erlotinib (TarcevaW, OSI-Pharmaceuticals, New
York, NY), which includes PDGFRA/B, KIT, C-ABL and
EGFR, were reported to be expressed in ESS and UES by
immunohistochemistry [26-40], although without presence
of any activating mutations [36-39,41,42]. Interestingly, a
few reports described objective responses with imatinib in
patients who express at least one TKI target [36,37,43].
Another report described a unique case of UES with
EGFR expression and EGFR amplification which tempor-
arily responded to imatinib [42]. Based on these findings,
an extensive evaluation of the molecular targets of TKI
on EST was carried out to identify a novel therapeutic
strategy for these malignancies. In the present study we
analyzed the gene status and protein expression of KIT,
PDGFRA, and EGFR in a large series of ESS and UES to
evaluate their distribution among the distinct subgroups
and correlate the immunohistochemical expression with
mutational status.
Material and methods
Patient selection and study design
A series of 75 EST was retrieved from Spanish centers
associated to Spanish Sarcoma Group (GEIS) and from
the Pathology Departments of Complejo Hospitalario
Universitario de Badajoz, Badajoz, Spain and Hospital do
Espírito Santo E.P.E, Évora, Portugal, and sent to Tumor
Bank of the Cancer Research Centre – Salamanca, Spain.
The selection of patients was made according to the
following inclusion criteria - previous diagnosis of EST
(any histological grade) and availability of histological
material sufficient to perform the study. After receiving
and encoding the samples, cases were reviewed and
subclassified by 1 co-author (EA) based on the current
WHO classification [2]. The study was approved by the
Ethics Committee of Hospital Germans Trias i Pujol
(Spain), and was conducted in accordance with the
Declaration of Helsinki and Spanish regulative law for
Tumor Banks.
Tissue microarray and immunohistochemistry
65 samples were considered valid and included in the
study. Ten cases were discarded because of a sample too
small to perform the proposed study or non-representative
sample or diagnosis different than EST. Before tissuemicroarray (TMA) construction, representative areas of
tumor were selected on hematoxylin and eosin (H&E) sec-
tion and marked on the paraffin block. For each sample
were obtained two cylinders of 1 mm diameter and placed
in a recipient block using a tissue microarrayer (Manual
Tissue Array; Beecher Instruments Inc. Sun Prairie,
Wisconsin, USA). In total two TMAs were constructed
according to previously described [44].
The tyrosine kinase receptors (TKR) evaluated were KIT,
PDGFRA and EGFR, and to confirm diagnosis the expres-
sion of two markers most commonly used on ESS [45,46],
CD10 and Calponin were assessed in each tumor. Immu-
nohistochemistry (IHC) was performed in 3 μm sections.
KIT, PDGFRA, CD10 and Calponin immunostaining was
performed using a DiscoveryW Ventana automated
immunostainer (Ventana Medical Systems, Tucson, Ari-
zona, USA). Heat-induced antigen retrieval was done with
Tris-EDTA buffer (pH 8.0) for KIT, PDGFRA and
Calponin and with citrate buffer (pH 6.0) for CD10. Sec-
tions were incubated with the primary antibodies Calponin
(clone CALP; Dako, Carpinteria, CA, USA), KIT (poly-
clonal; Dako, Carpinteria, CA, USA), PDGFRA (polyclonal;
Thermo Fisher Scientific, Fremont, CA, USA) and CD10
(clone 56C6; Novocastra Laboratoires, Newcastle upon
Tyne, UK) at 1:100 dilution. Universal secondary
biotinylated antibody (Discovery™ Universal Secondary
Antibody, Ventana Medical Systems, Tucson, Arizona,
USA) was used and developed for detection using the DAB
MAP system (Ventana Medical Systems, Tucson, Arizona,
USA). For EGFR analysis expression, a ready-to-use mono-
clonal antibody (clone 2.1E1; Gennova Scientific, Seville,
Spain) was used. Briefly, paraffin-embedded sections were
deparaffinized in xylene and rehydrated in downgraded al-
cohols and distilled water. Antigen retrieval was performed
with Proteinase K solution (Dako, Carpinteria, CA, USA).
The primary antibody was detected using a secondary
antibody- horseradish peroxidase polymer conjugate (Dako
REAL™ EnVision™ Detection System; Dako, Carpinteria,
CA, USA), and all incubations were done with the Dako
Autostainer Plus system (Dako, Carpinteria, CA, USA). All
sections were counterstained with hematoxylin, upgraded
alcohols, and xylene, mounted, and analyzed by standard
light microscopy.
Immunohistochemical evaluation
The expression of CD10 and Calponin was considered
positive when over 1% of the tumor cells showed cyto-
plasmic expression. The TKR expression was detected in
the cytoplasm of tumor cells, and each case was
interpreted for immunoreactivity using a 0 to 3 semi-
quantitative scoring system for both the intensity of stain
and the percentage of positive cells, as previously
reported [47]. The multiplicative index of intensity and
labeling was considered for statistic analysis and the
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plicative index 1–3, moderate local or diffuse for a
multiplicative index 4–6 and intense and diffuse if the
multiplicative index was >6. The IHC analysis was
scored by the same co-author who performed the histo-
logic review (EA).Molecular analysis of tyrosine kinase receptors
DNA extraction
Ten serial 5 μm sections were cut and transferred into
15 ml conical centrifugation tubes and deparaffinized in
xylene (two times for 5 minutes) and absolute ethanol
(two times for 5 minutes) at 4000 rpm, followed by
drying of the samples at room temperature. Subse-
quently, DNA extractions were performed according to
QIAamp DNA Mini Kit protocol (Qiagen, Hilden,
Germany), and then quantified by spectrophotometry
(SmartSpec Plus Spectrophotometer, Bio-Rad Laboratories
Inc., CA, USA).Table 1 EGFR oligonucleotide sequences for PCR analysis
Exon Specific primers PCR product
Exon 18 F : 50- GCT GAG GTG ACC CTT GTC TC -30 225 bp
R: 50- CTC CCC ACC AGA CCA TGA -30
Exon 19 F: 50- CAT GTG GCA CCA TCT CAC A -30 230 bp
R: 50- CAG CTG CCA GAC ATG AGA A -30
Exon 20 F: 50- CAT TCA TGC GTC TTC ACC TG -30 377 bp
R: 50- CAT ATC CCC ATG GCA AAC TC -30
Exon 21 F: 50- GCT CAG AGC CTG GCA TGA A -30 348 bp
R: 50- CAT CCT CCC CTG CAT GTG T -30
F: forward primer; R: reverse primer.KIT and PDGFRA
According to previous studies [48-50], exons 9, 11, 13,
and 17 of KIT gene and exons 12 and 18 of PDGFRA
gene were amplified in order to identify possible muta-
tions. Amplification of GAPDH gene was performed to
confirm integrity and quality of extracted DNA. PCR
amplification of KIT and PDGFRA was performed using
1–5 μl of genomic DNA, 1X PCR buffer + 2 mM MgCl2
(Roche Applied Science, Mannheim, Germany), 0.15 mM
of each primer, 200 μM of each dNTP (GeneAmpW
dNTP Blend, 10 mM, ABI, Carlsbad, CA, USA), and
1.5 U of Taq DNA polymerase (Roche Applied Science,
Mannheim, Germany) in a total volume of 25 μl. The
PCR conditions were 94°C for 10 min, 40 cycles of
1 min at 94°C, 1min30sec to 56°C (KIT) or 65°C
(PDGFRA) and 1 min at 72°C, followed by a cycle of
10 min at 72°C. The amplified products were visualized
on agarose gel 2%.
Prior to sequence analysis, KIT and PDGFRA PCR
products were first purified using a QIAquickW PCR
Purification Technology Kit (Qiagen, Hilden, Germany).
Direct sequencing of PCR products was performed using
ABI PRISMW BigDye Terminator Cycle Sequencing Kit
in an ABI Prism 3100 Genetic Analyzer (Applied
Biosystems, Carlsbad, CA, USA) according to the manu-
facturer instructions. Sequencing primers were the same
as those used for PCR, and both strands (forward and
reverse) were sequenced.
All sequences obtained were visualized and analyzed in
the program Sequence Scanner Software v1.0 (Applied
Biosystems, Carlsbad, CA, USA), based on the reference
sequences: KIT - ENSG00000157404 and PDGFRA -
ENSG00000134853.EGFR
PCR amplification of exons 18, 19, 20 and 21 of the
EGFR gene, which encompass most of the EGFR muta-
tions [51,52], was carried out using previously described
primers [53,54] (Table 1). Using 4 μl of DNA, PCR was
performed in a reaction volume of 15 μl containing 1X
PCR buffer (Applied Biosystems, Carlsbad, CA, USA),
2.5 mM MgCl2 (Applied Biosystems, Carlsbad, CA,
USA), 0.17 mM of each primer, 200 mM of each dNTP
(GeneAmpW dNTP Blend, 10 mM, Applied Biosystems,
Carlsbad, CA, USA) and 2 U of Taq DNA polymerase
(AmpliTaq GoldW DNA Polymerase, Applied Biosystems,
Carlsbad, CA, USA).
The conditions for PCR were 95°C for 12 min, 40 -
cycles of 30 sec at 95°C, 45 sec at 65°C and 1 min at
72°C, followed by a cycle of 10 min at 72°C. After
visualization of amplified products by gel electrophoresis
on a 2% agarose, these were purified with USBW
ExoSAP-ITW (Affymetrix, Inc., Cleveland, Ohio, USA).
Subsequently the purified products were precipitated
and labeled with GenomeLab™ DTCS Quick Start Kit
(Beckman Coulter Inc, Fullerton, CA, USA) according to
the manufacturer’s instructions and were sequenced
using GenomeLab™ GeXP Genetic Analysis System
(Beckman Coulter Inc, Fullerton, CA, USA). As de-
scribed above, sequencing was performed in both direc-
tions, and the same PCR primers were used.
The sequences were analyzed using Genome Lab
Genetic Analysis System v10.0.30 (Beckman Coulter Inc,
Fullerton, CA, USA), and compared with the reference
sequence ENSG00000146648.
Fluorescence in situ hybridization - EGFR
The ploidy status of EGFR in each tumor was assessed by
fluorescence in situ hybridization (FISH) on previously
constructed TMAs. Gene amplification was determined
by using an EGFR/CEN-7 FISH Probe Mix (Y5500, Dako,
Carpinteria, CA, USA) containing Texas Red-labeled
DNA probe covering the full EGFR region and a mixture
of fluorescein-labeled PNA probes targeted at the centro-
meric region of chromosome 7 (Chr7).
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Accessory Kit (Dako, Carpinteria, CA, USA), according
to the manufacturer’s instructions.
Hybridization signals were visualized using fluorescence
microscope equipped with a IAI monochrome progressive
scan (IAI Company, Taiwan) and run by image analysis soft-
ware CytovisionW (Leica Microsystems, Wetzlar, Germany).
20 tumour nuclei/case were scored, and the tumor cells in
which the signals of EGFR and CEP7 were increased equally
were classified as polysomy 7 and those for which there was
a double signal for EGFR or CEP7 were considered dip-
loid. To assess gene amplification, we calculated the
ratio of EGFR to CEP7 and evaluated in accordance
with the criteria of FISH scoring system of Colorado
Group [55]. Evaluation of the ploidy status of EGFR
was performed by a single pathologist (EA).
Statistical analysis
The association between the expression of TKR and
ploidy of EGFR with different histological types of EST,
as well the mutational status of TKR were assessed. All
statistical analyses were performed based on contingency
tables, with SPSS software v18.0 statistics (Chicago,
Illinois).
Results
Classification of endometrial stromal tumors
From 65 EST cases, 80% (52/65) were diagnosed as ESS,
and 20% (13/65) were UES. As expected, the majority of
ESS presented expression of CD10, 51.9% (27/52), which
was lower in UES cases (23.1%; 3/13).
Analysis of expression of tyrosine kinase receptors
The expression of KIT, PDGFRA and EGFR was evalu-
ated in all cases of EST, and an example of the pattern
of expression of these markers is shown in Figure 1.
KIT stromal expression was found in only 2 out of 65
cases, and it was weak and/or focal. In contrast,
PDGFRA showed positive stromal expression in 35.4%
of cases (23/65), mostly weak and/or focal; its distribu-
tion was similar in both histological subtypes. Interest-
ingly, expression was not intense and/or diffuse in any
case. For EGFR, a minority of cases were classified as
positive, representing 10.8% (7/65).
Mutational status of tyrosine kinase receptors
The molecular study was performed in 62 cases. Sequen-
cing of exons 9, 11, 13 and 17 of KIT only revealed the
presence of a silent base substitution (ATC>ATT) in
exon 17 at codon 798 (I798I) in two cases (ESS). The
PDGFRA analysis showed the presence of several silent
mutations, a base substitution (CCA>CCG) in exon 12
at codon 567 (P567P) in all cases, 32.3% (21/65) showed
a silent base substitution (GTC>GTT) in exon 18 atcodon 824 (V824V) and 1 case had a double silent base
substitution at codons 824 and 838 (GTC>GTT and
GGC>GGT; V824V and G838G respectively) both in
exon 18. There were no somatic mutations in the genes
KIT and PDGFRA.
EGFR mutational analysis was performed only in cases
with expression of EGFR, and in which DNA was avail-
able for molecular studies. Two cases without EGFR
expression were included as control. There were no mu-
tations in EGFR exons 18, 19, 20 and 21. In 6 of 7 cases
silent base substitution were identified at codon 787
(CAG>CAA; Q787Q), and in one of these cases were
identified another silent base substitution at codon 790
(ACG>ACA; T790T) both in exon 20.EGFR amplification by FISH
EGFR gene amplification analysis was performed in all
cases included in the study (65 cases), except in one
which was considered not evaluable. No amplification of
EGFR gene was observed. Numerous cases (58/64,
90.6%) were diploid (1–2 copies), and few cases (6/64,
9.4%) were polyploid (3–4 copies), and the distribution
was similar in both histological types.Discussion
Systemic therapy in EST has a marginal efficacy. Low
grade ESS can achieve control with hormonal treat-
ments (progestins, aromatase inhibitors) and high grade
undifferentiated uterine sarcomas are included in clin-
ical trials together with leiomyosarcomas. Tanner et al.
reported efficacy of docetaxel and gemcitabine or
adriamycin for advanced cases of high grade endomet-
rial tumors [56]. Indeed, the indication of systemic
treatment of EST is controversial. Hormonal treatment
can depend on hormonal receptor status and is as-
sociated to light side-effects and occasionally indi-
cated. Responses were reported in a few ESS cases
treated with progestin or aromatase inhibitors [57-64],
but prospective larger trials are needed. Chemotherapy
showed no apparent benefit in ESS [34,65-67]. In the
case of UES some objective and partial responses were
observed [68-70]. In a retrospective study including
only 21 patients was described a response rate of 62%
with gemcitabine/docetaxel and doxorubicin-based reg-
imens in first-line, whereas in second- or additional
chemotherapy for progressive disease, the response rate
was around 19% [56]. On the other hand, radiotherapy
seems to have a significant effect on local-regional con-
trol rate with a low impact on survival improvement
[3,4,71-74]. Due to these facts several reports address
the need to explore the role of TKR in these malignan-
cies. The possible clinical efficacy of imatinib in the
treatment of EST and the contribution of its TKR-
Figure 1 Immunohistochemical expression of tyrosine kinase receptors in endometrial stromal tumors. Endometrial stromal sarcoma, low
grade (A) and undifferentiated endometrial sarcoma (B). Negative expression of KIT in ESS (C) and very focal expression in UES (D). Weak and/or
focal PDGFRA and EGFR expression in ESS (E, G) and UES (F,H).
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solve [34].
Previous reports showed the presence at least one
TKR in EST, but available data just refer a few case re-
ports and small series, which makes it difficult to draw
conclusions. Based on this, we performed an extensive
evaluation of molecular and immunohistochemical ex-
pression of TKR KIT, PDGFRA and EGFR in a large
series of ESS and UES.KIT and PDGFRA cytoplasmic expression was ob-
served in 3% and 35.4% respectively. In the litera-
ture, KIT expression has been reported to be quite
variable (0-100%) (Table 2) and this might be due
to differences in the choice of antibody clones, tis-
sue pretreatment, sensitivity of immunohistochemical
procedures, sample selection and use of whole tissue
sections or TMA sections, which was also suggested
in previous studies [75,76]. On the other hand,
Table 2 TKR expression on endometrial stromal tumors
Author KIT (%) PDGFRA (%) EGFR (%)
ESS UES ESS UES ESS UES
Oliva, Young et al. [79] 0/8 (0)
Hornick and Fletcher [80] 0/10 (0)
Winter, Seidman et al. [81] 0/1 (0)
Wang, Felix et al. [26] 3/11 (27) 2/3 (67)
Rushing, Shajahan et al. [27] 2/2 (100)
Klein and Kurman [28] 1/10 (10) 0/2 (0)
Leath, Straughn et al. [29] 3/3 (100)
Caudell, Deavers et al. [35] 0/8 (0) 1/4 (25)
Moinfar, Gogg-Kamerer et al. [40] 14/20 (70) 3/3 (100)
Salvatierra, Tarrats et al. [36] 1/1 (100)
Nakayama, Mitsuhashi et al. [76] 0/5 (0)
Liegl, Gully et al. [38] 0/37 (0) 22/37 (59)
Adams, Hickson et al. [39] 0/8 (0) 7/8 (88)
Mitsuhashi, Nakayama et al. [42] 0/1 (0) 1/1(100)
Zafrakas, Theodoridis et al. [31] 2/2 (100) 1/2 (50)
Martin, Ramesh et al. [32] 1/1 (100)
Trojan, Montemurro et al. [37] 0/1 (0) 1/1 (100)
Koivisto-Korander, Butzow et al. [33] 2/9 (22)
Cheng, Yang et al. [34] 1/12 (8) 4/12 (33)
Cossu-Rocca, Contini et al. [77] 0/23 (0) 1/5 (20) 15/23 (65) 4/5 (80) 10/23 (43) 4/5 (80)
Park, Kim et al. [78] 32/39 (82.1) 28/39 (71.8) 0/39 (0)
Present series (2013) 1/52 (2) 1/13 (7.7) 18/52 (34.6) 5/13 (38.5) 6/52 (11.5) 1/13 (7.7)
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mostly weak and/or focal, lies within the range
reported in previous studies [34,37-39,77,78].
In our series, mutational analysis of hot spots of KIT
and PDGFRA genes did not reveal any somatic muta-
tion, which is consistent with previous studies
[36-39,41,42,77]. Constitutive activation via autocrine/
paracrine stimulation of the receptor by its ligand was
observed in several human cancers and is related with
their tumorigenesis [82,83]. Probably, expression of
related ligands of KIT and PDGFRA, which were not
evaluated in this series, might be the reason for expres-
sion of both receptors in these tumors, although more
studies are needed. Second, the work of Kang et al. dem-
onstrated that relative KIT expression ratio was fivefold
higher in cases with KIT mutation, than in GISTs lack-
ing KIT mutation and the mutation status of KIT and
PDGFRA was directly related to the different expression
levels of activated KIT and PDGFRA [84]. Furthermore,
with exception of GISTs, the presence of overexpression
of KIT and PDGFRA in human cancers was not corre-
lated with presence of activating mutations [85]. These
facts support our results, once that KIT and PDGFRA
expression observed was mostly weak and/or focal andlacks activating mutations on its related genes. Further-
more, the consistent expression of KIT and PDGFR
receptors and their ligands was seen in a phase II trial in
women with ovarian cancer, together with the absence
of mutations in these genes and with lack of response to
imatinib [86]. In other two phase II clinical trials in lung
cancer [87] and uterine carcinosarcomas [88], the high
expression of KIT did not correlate with response to
imatinib. These clinical findings support the hypothesis
that overexpression of these TKR does not confer sensi-
tivity to imatinib, which was previously suggested for
other uterine sarcomas [89].
However, the expression of at least one of imatinib-
target (KIT, PDGFRA and PDGFRB) without evidence of
activating mutations was reported in EST patients who
responded to imatinib treatment [36,37,43]. Tumor
shrinkage was the main indicator of objective response
accompanied by stable disease in two cases [36,37]. One
explanation for these results may be due to the autocrine/
paracrine signaling of PDGFRB. In dermatofibrosarcoma
protuberans (DFSP), t(17;22)(q22;q13) results in a
COL1A1-PDGFB gene fusion. This cytogenetic abnormal-
ity is essential for pathogenesis of the disease and respon-
sible by constitutive activation of PDGFRB. Imatinib
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decreases enzymatic activity in DFSP cells and inhibits
their ability to divide and grow [91] and induces apoptosis
in tumor cells [92], which may have effects on decreasing
tumor size [93]. In fact, an effect of imatinib on tumor
shrinkage was observed in patients with DFSP [94,95], and
therefore imatinib was approved for unresectable, recur-
rent, and/or metastatic DFSP in adults. However, in ESS
and UES cases reported as responsive to imatinib,
PDGFRB was only determined in one case reported by
Trojan et al. [37], which makes difficult to draw any
conclusions.
Concerning EGFR expression, our study reveals lower
cytoplasmic expression of EGFR in EST cases (around
10.8%), in contrast with the results obtained by other
authors [40,77] (Table 2). This contradiction may be a
consequence of the same variables indicated for the
immunoexpression of KIT. Since i) a correlation
between an increased EGFR copy number and gefitinib
was proposed in non-small-cell lung cancer (NSCLC)
[96] and ii) immunohistochemistry is not a reliable ap-
proach for this determination, we decided to evaluate
EGFR amplification status in our series by FISH. The
EGFR/Chr7 ratio was below 2, which is indicative of
non-amplification, and only a small percentage of the
cases presented polysomy. Previous evaluation of EGFR
amplification was only performed in a UES case which
presented a temporary response to imatinib. This case
presented a low-level amplification (mean ratio 2.9)
according to the evaluation criteria of the authors [42].
Although no consensus has been reached on how
to assess the presence and extent of EGFR status
dysregulation in solid tumors by FISH analysis [97], it
seems likely that gene amplification found in NSCLC
and glioblastoma is an uncommon event in EST. EGFR
mutational status also did not show any somatic muta-
tion in exons 18–21. In fact, all these data confirm that
it is unlikely that EGFR activation could play a role in
tumorigenesis of EST.
Conclusions
In summary, we performed an extensive molecular and
expression analysis of KIT, PDGFRA and EGFR in the
largest series of EST studied so far (Table 2). Our find-
ings reveal a lack of significant expression, amplification
and activating mutations on these receptors and related
genes, which suggests that it is unlikely that EST can
benefit from therapies such as imatinib or EGFR inhibi-
tors in advanced disease. However, the role of imatinib
in the management of unresectable tumors needs to be
clarified through evaluation of expression of constitutive
activation of PDGFRB by its ligands, or other genetic
alterations in ESS and UES. The recent discovery of a
chromosomal rearrangement t(10;17)(q22;p13) thatresults in a 14-3-3 fusion protein with oncogenic proper-
ties in a subgroup of UES [22], and the nuclear expres-
sion of β-catenin, a member of Wnt and E-cadherin
signaling pathways in EST need to be better explored,
since they can represent an entry point for targeted
therapeutic strategies.
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